当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Manuel Aparicio-Alonso, Carlos A. Domínguez-Sánchez and Marina Banuet-Martínez
Frontline in December 2019, the first case of COVID-19 was reported in Wuhan, China and spread rapidly worldwide. This disease
has caused millions of deaths, and to date, there is no fully effective drug against this disease. This study evaluated the negative and
positive effects of Chlorine Dioxide (ClO2) as an alternative therapy for the treatment of COVID-19. Information was collected from the
medical records of 1,136 patients treated for COVID-19 with three different protocols of a ClO2 aqueous solution at a mean dose of 1.41
mg/kg. The average time of the resolution of the symptoms was 4.84 days, and the complete treatment lasted 15.87 days. Furthermore,
6.78% of the patients presented mild and sporadic adverse reactions such as headache, dizziness, vomiting, diarrhea and nausea. No
side effects endangered the health of the patients. Blood tests did not reveal any systemic abnormalities after ClO2 consumption. Hepatic
enzymes, glucose, total cholesterol, and triglycerides decreased to normal at the end of treatment. Without any complications, 99.03%
of the patients were discharged. Our findings show that, when used at the appropriate concentration and dosage, ClO2 as a solution
effectively treats COVID-19 while also being safe for human consumption.